Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting
Journal of the American Geriatrics Society · 2024-09 · 72 (9) · 2700-2708
DOI: 10.1111/jgs.19045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 26.06.2024. Verfasst von Mike Wenzel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
The landscape of systemic therapies for metastatic hormone‐sensitive (mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the last decades resulting in a significantly prolonged overall survival. However, subgroup analyses of phase III trials suggest potentially different overall survival outcomes for older adults.
Methods
We relied on our institutional metastatic prostate cancer database to identify mHSPC and subsequently mCRPC patients. Older adults were stratified according to age groups 70–74 versus ≥75–79 versus ≥80 years at metastatic occurrence. Subsequently, uni‐ and multivariable time to mCRPC and overall survival analyses were performed.
Results
Of 494 older adults, 217 (44%) were 70–74 versus 180 (36%) 75–79 versus 97 (20%) ≥80 years old. Rates of local prostate cancer treatment differed significantly between all three groups ( p < 0.01). Regarding mHSPC treatment, androgen receptor signaling inhibitors (ARSI) were administered in 30–39% of patients and docetaxel with 9% in age group 70–74 years and 6% and 3% in age groups 75–79 years and ≥80 years. Regarding mCRPC treatment, significant differences between treatment proportions were observed ( p < 0.01). Most common treatment was ARSI for all three groups. Conversely, chemotherapy was more frequently administered in patients aged 70–74 (16%), relative to 4% and 3% in 75‐79 year and ≥80 year aged patients. In univariable and multivariable time to mCRPC analyses, overall survival in mHSPC and OS in mCRPC analyses, no significant differences between all three age groups were observed (all p ≥ 0.3).
Conclusions
Treatment patterns differ significantly between older adults with metastatic prostate cancer. However, these differences may not result in differences of overall life expectancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, Koc University Hospital, Istanbul, Turkey.
ORCID-Profile: Mike Wenzel
Zitieren
APA
Wenzel, M., Hoeh, B., Wagner, N., Koll, F., Siech, C., Humke, C., Steuber, T., Graefen, M., Tilki, D., Kluth, L., Traumann, M., Banek, S., Chun, F. K. H., & Mandel, P. (2024). Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting. Journal of the American Geriatrics Society, 72(9), 2700-2708. https://doi.org/10.1111/jgs.19045
Vancouver
Wenzel M, Hoeh B, Wagner N, Koll F, Siech C, Humke C, et al. Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting. Journal of the American Geriatrics Society. 2024;72(9):2700-2708. doi:10.1111/jgs.19045
BibTeX
@article{Wenzel2024,
author = {Wenzel, Mike and Hoeh, Benedikt and Wagner, Nele and Koll, Florestan and Siech, Carolin and Humke, Clara and Steuber, Thomas and Graefen, Markus and Tilki, Derya and Kluth, Luis and Traumann, Miriam and Banek, Séverine and Chun, Felix K H and Mandel, Philipp},
title = {Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting},
journal = {Journal of the American Geriatrics Society},
year = {2024},
volume = {72},
number = {9},
pages = {2700--2708},
doi = {10.1111/jgs.19045}
}
EUVIMED